Rare Cancers Australia, and an army of peak cancer organisations, call on the Pharmaceutical Benefits Advisory Committee (PBAC) to expand access to the breakthrough PD-1/PD-L1 inhibitor class of medicines for the more than 3,500 Aussies who would benefit.
Read more arrow_forwardOver 650 people will be descending on Thredbo this week (15th & 16th March) to take on Australia’s highest peak, Mount Kosciuszko, in a charity challenge to raise awareness and vital funds for rare and less common cancers.
Read more arrow_forwardRare Cancers Australia has welcomed a recent approval by the TGA of the Novartis targeted therapy drug Tafinlar + Mekinist, which has proven to be effective in treating an extremely rare form of cancer mutation called BRAF 600E.
Read more arrow_forwardPioneering national genomics initiative gives 23,000 Australians their best fighting chance against the toughest cancers.
Read more arrow_forward
Rare Cancers Australia (RCA) has launched the country’s first comprehensive support guide dedicated to the unique challenges of a rare cancer experience.
Read more arrow_forward
On Tuesday 13th September 2022, leading charity Rare Cancers Australia (RCA) will launch a new online Thought Leader Series with some of the brightest minds in the Australian cancer community.
Read more arrow_forward
In the leadup to Rare Cancers Awareness Day on 26 June, RCA is celebrating 10 years of supporting Australians living with rare, less common, and complex cancers.
Read more arrow_forwardOn the eve of Rare Cancers Australia’s (RCA) ten-year anniversary, the cancer community is bidding farewell to co-founder and Chief Patient Officer, Kate Vines – Australia’s first cancer navigator to specialise in the rare cancer journey.
Read more arrow_forwardRemoving the financial toxicity from the cancer care journey Private Cancer Physicians of Australia and Rare Cancers Australia call for a Cancer Care Patient Safety Net.
Read more arrow_forwardThe Government has heeded the calls from Medicines Australia, patient groups, health bodies, and industry by extending the finalisation of the National Medicines Policy (NMP) Review until after the Federal election.
Read more arrow_forward